Erika M. Lisabeth

1.1k total citations
17 papers, 712 citations indexed

About

Erika M. Lisabeth is a scholar working on Molecular Biology, Cell Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Erika M. Lisabeth has authored 17 papers receiving a total of 712 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Cell Biology and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Erika M. Lisabeth's work include Melanoma and MAPK Pathways (3 papers), Protein Kinase Regulation and GTPase Signaling (3 papers) and Axon Guidance and Neuronal Signaling (3 papers). Erika M. Lisabeth is often cited by papers focused on Melanoma and MAPK Pathways (3 papers), Protein Kinase Regulation and GTPase Signaling (3 papers) and Axon Guidance and Neuronal Signaling (3 papers). Erika M. Lisabeth collaborates with scholars based in United States, Italy and Sweden. Erika M. Lisabeth's co-authors include Elena B. Pasquale, Richard R. Neubig, Scott D. Larsen, C. Fernández, Sean A. Misek, Thomas S. Dexheimer, Phillip L. Campbell, Dinesh Khanna, David A. Fox and Andrew J. Haak and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biochemistry.

In The Last Decade

Erika M. Lisabeth

15 papers receiving 703 citations

Peers

Countries citing papers authored by Erika M. Lisabeth

Since Specialization

Citations

This map shows the geographic impact of Erika M. Lisabeth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika M. Lisabeth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika M. Lisabeth more than expected).

Fields of papers citing papers by Erika M. Lisabeth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika M. Lisabeth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika M. Lisabeth. The network helps show where Erika M. Lisabeth may publish in the future.

Co-authorship network of co-authors of Erika M. Lisabeth

This figure shows the co-authorship network connecting the top 25 collaborators of Erika M. Lisabeth. A scholar is included among the top collaborators of Erika M. Lisabeth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika M. Lisabeth. Erika M. Lisabeth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Development of a 5-HT7 receptor antibody for the rat: the good, the bad, and the ugly 2023 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Janice Thompson, (unknown), (unknown), Stefan Schulz, Erika M. Lisabeth, Stephanie W. Watts	1
2	Development of a Cell-Based AlphaLISA Assay for High-Throughput Screening for Small Molecule Proteasome Modulators 2023 ·ACS Omega ·(unknown), Erika M. Lisabeth, (unknown), Thomas S. Dexheimer, Richard R. Neubig, Jetze J. Tepe	3
3	Revisiting Pirin: Evidence for a Role in Translation but not in Transcriptional Control 2023 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Richard R. Neubig, Erika M. Lisabeth	0
4	Without a Trace: The Pirin and NF-κB Interaction 2023 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Erika M. Lisabeth, Richard R. Neubig	0
5	Mass Spectrometry, Structural Analysis, and Anti-Inflammatory Properties of Photo-Cross-Linked Human Albumin Hydrogels 2022 ·ACS Applied Bio Materials ·Shahriar Sharifi, Amir Ata Saei, Hassan Gharibi, Nouf N. Mahmoud, (unknown), (unknown), Erika M. Lisabeth, Vahid Serpooshan, Ákos Végvári, Anna Moore, Morteza Mahmoudi	11
6	Transforming Growth Factor β1 Increases Expression of Contractile Genes in Human Pulmonary Arterial Smooth Muscle Cells by Potentiating Sphingosine-1-Phosphate Signaling 2021 ·Molecular Pharmacology ·(unknown), Erika M. Lisabeth, Richard R. Neubig	8
7	Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells 2019 ·Oncogene ·Sean A. Misek, (unknown), Thomas S. Dexheimer, Erika M. Lisabeth, Roger S. Lo, Scott D. Larsen, Kathleen A. Gallo, Richard R. Neubig	42
8	The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice 2019 ·Scientific Reports ·Ana S. Leal, Sean A. Misek, Erika M. Lisabeth, Richard R. Neubig, Karen T. Liby	20
9	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds 2019 ·ACS Pharmacology & Translational Science ·Erika M. Lisabeth, (unknown), Indiwari Gopallawa, Sarah E. Haynes, Sean A. Misek, Phillip L. Campbell, Thomas S. Dexheimer, Dinesh Khanna, David A. Fox, Xiangshu Jin, Brent R. Martin, Scott D. Larsen, Richard R. Neubig	30
10	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma 2019 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Erika M. Lisabeth, Andrew J. Haak, Jeffrey R. Leipprandt, Thomas S. Dexheimer, Dinesh Khanna, Pei‐Suen Tsou, Phillip L. Campbell, David A. Fox, Bo Wen, Duxin Sun, Marc B. Bailie, Richard R. Neubig, Scott D. Larsen	36
11	Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis 2017 ·Scientific Reports ·Cynthia Yu‐Wai‐Man, Bradley Spencer‐Dene, (unknown), (unknown), Erika M. Lisabeth, Richard Treisman, Maryse Bailly, Scott D. Larsen, Richard R. Neubig, Peng T. Khaw	54
12	Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma 2017 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Erika M. Lisabeth, Walajapet G. Rajeswaran, Michael W. Wilson, Roderick J. Sorenson, Phillip L. Campbell, Jeffrey H. Ruth, Asif Amin, Pei‐Suen Tsou, Jeffrey R. Leipprandt, Samuel R. Olson, Bo Wen, Ting C. Zhao, Duxin Sun, Dinesh Khanna, David A. Fox, Richard R. Neubig, Scott D. Larsen	40
13	Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma 2016 ·Molecular Cancer Therapeutics ·Andrew J. Haak, Kathryn M. Appleton, Erika M. Lisabeth, Sean A. Misek, (unknown), Susan M. Wade, Jessica L. Bell, Cheryl E. Rockwell, Merlin Airik, Melanie A. Krook, Scott D. Larsen, Monique Verhaegen, Elizabeth R. Lawlor, Richard R. Neubig	30
14	Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks 2016 ·SHILAP Revista de lepidopterología ·Chris R. Evelyn, Erika M. Lisabeth, Susan M. Wade, Andrew J. Haak, Craig Johnson, Elizabeth R. Lawlor, Richard R. Neubig	19
15	Attenuation of Eph Receptor Kinase Activation in Cancer Cells by Coexpressed Ephrin Ligands 2013 ·PLoS ONE ·(unknown), Erika M. Lisabeth, (unknown), Gizeh Pérez‐Tenorio, Giovanna Tosato, Ombretta Salvucci, Elena B. Pasquale	45
16	Eph Receptor Signaling and Ephrins 2013 ·Cold Spring Harbor Perspectives in Biology ·Erika M. Lisabeth, (unknown), Elena B. Pasquale	316
17	Cancer Somatic Mutations Disrupt Functions of the EphA3 Receptor Tyrosine Kinase through Multiple Mechanisms 2012 ·Biochemistry ·Erika M. Lisabeth, C. Fernández, Elena B. Pasquale	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact